KLP Kapitalforvaltning AS Purchases New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

KLP Kapitalforvaltning AS purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 76,900 shares of the company's stock, valued at approximately $358,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in GoodRx during the 3rd quarter valued at about $11,295,000. Franklin Resources Inc. bought a new stake in shares of GoodRx during the third quarter worth approximately $5,675,000. Raymond James Financial Inc. acquired a new position in GoodRx in the fourth quarter valued at approximately $2,500,000. Pier Capital LLC bought a new position in GoodRx in the third quarter valued at approximately $3,259,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in GoodRx by 38.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock valued at $5,714,000 after acquiring an additional 342,781 shares during the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Truist Financial decreased their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research note on Thursday. Wells Fargo & Company lowered their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Morgan Stanley cut their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. KeyCorp decreased their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Finally, Citigroup dropped their target price on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and an average price target of $7.93.

Remove Ads

GoodRx Stock Performance

Shares of GDRX traded down $0.37 during mid-day trading on Thursday, reaching $4.32. The company's stock had a trading volume of 1,136,167 shares, compared to its average volume of 1,381,071. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 1-year low of $3.82 and a 1-year high of $9.26. The business has a 50-day simple moving average of $4.66 and a two-hundred day simple moving average of $5.08. The stock has a market cap of $1.66 billion, a P/E ratio of -144.00, a PEG ratio of 2.46 and a beta of 1.25.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.